Literature DB >> 6209527

Immunosuppression with monoclonal antibodies. A model to determine the rules for effective serotherapy.

S P Cobbold, S Thierfelder, H Waldmann.   

Abstract

Despite the range of available T cell specific monoclonal antibodies, there are no established rules to predict which might be immunosuppressive. We here describe a series of five rat monoclonal antibodies to a defined T cell antigen (mouse Thy-1) and evaluate their ability to immunosuppress mice. When compared with rabbit anti-lymphocyte globulin, only one of these monoclonal antibodies was able to delay skin allograft rejection and eliminate antibody responses to sheep red blood cells. This antibody was immunosuppressive following intra-peritoneal administration, even though it did not eliminate all of the T cells in vivo. Two factors may be relevant in determining the immunosuppressive properties of this reagent. First, the monoclonal antibody is of the rat IgG2b sub-class, and second, the specificity of the antibody is different to the other monoclonal antibodies in that it reacts with sub-populations of peripheral T cells, thymocytes and non-T cells. In practice, this suggests that to derive suitable monoclonal antibodies for human serotherapy, one should give attention to both the subclass and the fine specificity of the antibody for the target molecule.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6209527

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  5 in total

1.  Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Authors:  L K Gilliland; M R Clark; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

2.  Combined prophylactic suppression of graft-versus-host and host-versus-graft reactions following treatment of prospective bone marrow recipients with rat IgG 2b anti-mouse T cell antibodies.

Authors:  S Thierfelder; U Kummer; G Hoffmann-Fezer; R Schuh
Journal:  Blut       Date:  1986-04

3.  A personal history of the CAMPATH-1H antibody.

Authors:  Herman Waldmann
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

4.  Advances in the applications of monoclonal antibodies in clinical oncology. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

5.  Tolerance to rat monoclonal antibodies. Implications for serotherapy.

Authors:  R J Benjamin; S P Cobbold; M R Clark; H Waldmann
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.